NCT00055861 arm group 97a775f2632cc7bf674ac7fcf817c2f4 [clinicaltrials_resource:NCT00055861/arm-group/97a775f2632cc7bf674ac7fcf817c2f4]
laboratory biomarker analysis [clinicaltrials_resource:4c215c028c472233edd0accb1c4a43dd]bevacizumab [clinicaltrials_resource:9cb7c60a9c78c92fa3792a4eb7085831]docetaxel [clinicaltrials_resource:d90273428fa3f4b22e58b17e5c47b9d8]Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer [clinicaltrials:NCT00055861]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00055861 arm group 97a775f2632cc7bf674ac7fcf817c2f4 [clinicaltrials_resource:NCT00055861/arm-group/97a775f2632cc7bf674ac7fcf817c2f4]
Bio2RDF identifier
NCT00055861/arm-group/97a775f2632cc7bf674ac7fcf817c2f4
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... a775f2632cc7bf674ac7fcf817c2f4
description [clinicaltrials_vocabulary:description]
Patients receive bevacizumab I ...... xicity or disease progression.
identifier
clinicaltrials_resource:NCT00055861/arm-group/97a775f2632cc7bf674ac7fcf817c2f4
title
NCT00055861 arm group 97a775f2632cc7bf674ac7fcf817c2f4
@en
type
label
NCT00055861 arm group 97a775f2 ...... 775f2632cc7bf674ac7fcf817c2f4]
@en